FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564822114> ?p ?o ?g. }

• W2564822114 endingPage "4144" @default.
• W2564822114 startingPage "4144" @default.
• W2564822114 abstract "Abstract The Epstein-Barr virus (EBV) is an oncogenic, γ-herpesvirus associated with a broad spectrum of disease. While most immune-competent individuals can effectivley develop efficient adaptive immune responses to EBV, immunocompromised individuals are at serious risk for developing lifethreatening pathology such as Hodgkin’s lymphoma and post-transplant lymphoproliferative disorder (PTLD). Given the significant morbidity associated with EBV in high-risk populations, there is a need to develop vaccine strategies that restore or enhance EBV-specific immune responses. Here, we identify the EBV immediate-early protein BZLF1, a transcription factor that initiates latency to lytic cycle transition, as a potential target antigen for vaccine development. IHC assays on primary lymphoma samples from patients with PTLD and a chimeric human-murine model of EBV-driven lymphoproliferative disorder (EBV-LPD) revealed significant expression of BZLF1 protein (>10% tumor cells). Other EBV-positive lymphomas that exhibited staining for BZLF1 included lymphomatoid granulomatosis (1/3) and diffuse large B-cell lymphoma (5/10); whereas EBV(+) Hodgkin’s and EBV(+) unclassifiable lymphomas failed to demonstrate any BZLF1 signal. To examine the immunomodulatory properties of BZLF1, PBMCs were isolated from 24 healthy, EBV-seropositive donors of various HLA types and cultured in vitro with adenovirus encoding recombinant BZLF1 (rAd5F35/BZLF1) or null control (rAd5F35/null) for 18 hrs. Quantification of the number of IFN-γ secreting cells by ELISPOT revealed increased immune activation in response to BZLF1 exposure in the majority (20/24) of donors. These results led us to hypothesize that enhanced recognition of BZLF1 by antigen-specific cellular immunity may provide a protective effect against EBV. To address this, we next investigated whether DCs loaded with recombinant BZLF1 protein could mediate the expansion of BZLF1-specific CD8(+) T-cells in vitro. DCs were generated in vitro from healthy PBMC monocytes. Coculture of rBZLF1-loaded DCs and autologous PBMCs led to increased frequencies of BZLF1-specific CD8(+) T-cells as determined by tetramer flow assays. To determine whether BZLF1 vaccination could prime BZLF1-specific T-cell immunity in vivo, SCID mice depleted of murine NK cells were engrafted with EBV-positive PBMCs (hu-PBL-SCID) and injected simultaneously with rBZLF1 (100 µg/mouse). Four weeks post-vaccination, ex vivo splenocytes were reexposed to BZLF1-presenting DCs in vitro and assayed for IFN-γ secretion by ELISPOT. In comparison to vehicle, vaccination with rBZLF1 alone significantly enhanced BZLF1-specific IFN-γ responses (p=0.0007, n=3). In order to generate broader, more sustained immune responses against BZLF1, we next explored BZLF1 virally-transduced DC vaccination as a potential approach to prevent EBV-LPD. Monocyte-derived DCs were infected with rAd5F35/BZLF1 or rAd5F35/null (MOI=10) and cocultured with autologous PBMCs for 7 days. Exposure to BZLF1-transduced DCs induced a robust expansion of BZLF1-specific CD8(+) cells that was comparatively higher than recombinant protein presentation. Finally, we examined whether vaccination of hu-PBL-SCID mice with rAd5F35/BZLF1-transduced DCs would positively enhance cellular immunity and improve survival against fatal EBV-LPD. Hu-PBL-SCID mice were injected IP with 5 x 106 BZLF1-transduced DCs (or control). Mice in the “booster group” received a second dose of either rAd5F35/BZLF1 (or control) DCs as a booster. Five weeks post-vaccination, ex-vivo splenocytes were cultured 1:1 with autologous lymphoblastoid cell lines (LCLs) and assayed for IFN-γ secretion by ELISPOT. Mice vaccinated with rAd5F35/BZLF1-transduced DCs showed significantly higher responsiveness to LCLs relative to vector control mice (p<0.0001, n=3). Furthermore, single vaccination with BZLF1-transduced DCs showed a trend toward improved survival (p=0.085, n=10); however, vaccination followed by booster delivery at 2 weeks significantly delayed the development of EBV-LPD (p=0.014, n=10, median survival: rAd5F35/BZLF1, 62 days; rAd5F35/null, 48 days). These findings identify BZLF1 as a candidate target protein in the immunosurveillance of EBV and provide rationale for considering BZLF1 in vaccine strategies to enhance primary and recall immune responses and potentially prevent EBV-associated diseases. Disclosures No relevant conflicts of interest to declare." @default.
• W2564822114 created "2017-01-06" @default.
• W2564822114 creator A5012846289 @default.
• W2564822114 creator A5018821266 @default.
• W2564822114 creator A5020421383 @default.
• W2564822114 creator A5024627457 @default.
• W2564822114 creator A5034147671 @default.
• W2564822114 creator A5036655213 @default.
• W2564822114 creator A5038152941 @default.
• W2564822114 creator A5039845129 @default.
• W2564822114 creator A5049192022 @default.
• W2564822114 creator A5054228072 @default.
• W2564822114 date "2014-12-06" @default.
• W2564822114 modified "2023-10-16" @default.
• W2564822114 title "The Epstein-Barr Virus Lytic Protein BZLF1 As a Candidate Target Antigen for Vaccine Development" @default.
• W2564822114 doi "https://doi.org/10.1182/blood.v124.21.4144.4144" @default.
• W2564822114 hasPublicationYear "2014" @default.
• W2564822114 type Work @default.
• W2564822114 sameAs 2564822114 @default.
• W2564822114 citedByCount "0" @default.
• W2564822114 crossrefType "journal-article" @default.
• W2564822114 hasAuthorship W2564822114A5012846289 @default.
• W2564822114 hasAuthorship W2564822114A5018821266 @default.
• W2564822114 hasAuthorship W2564822114A5020421383 @default.
• W2564822114 hasAuthorship W2564822114A5024627457 @default.
• W2564822114 hasAuthorship W2564822114A5034147671 @default.
• W2564822114 hasAuthorship W2564822114A5036655213 @default.
• W2564822114 hasAuthorship W2564822114A5038152941 @default.
• W2564822114 hasAuthorship W2564822114A5039845129 @default.
• W2564822114 hasAuthorship W2564822114A5049192022 @default.
• W2564822114 hasAuthorship W2564822114A5054228072 @default.
• W2564822114 hasConcept C147483822 @default.
• W2564822114 hasConcept C159047783 @default.
• W2564822114 hasConcept C182615771 @default.
• W2564822114 hasConcept C203014093 @default.
• W2564822114 hasConcept C2522874641 @default.
• W2564822114 hasConcept C2776409557 @default.
• W2564822114 hasConcept C2780727368 @default.
• W2564822114 hasConcept C2781295983 @default.
• W2564822114 hasConcept C2781375147 @default.
• W2564822114 hasConcept C86803240 @default.
• W2564822114 hasConcept C8891405 @default.
• W2564822114 hasConceptScore W2564822114C147483822 @default.
• W2564822114 hasConceptScore W2564822114C159047783 @default.
• W2564822114 hasConceptScore W2564822114C182615771 @default.
• W2564822114 hasConceptScore W2564822114C203014093 @default.
• W2564822114 hasConceptScore W2564822114C2522874641 @default.
• W2564822114 hasConceptScore W2564822114C2776409557 @default.
• W2564822114 hasConceptScore W2564822114C2780727368 @default.
• W2564822114 hasConceptScore W2564822114C2781295983 @default.
• W2564822114 hasConceptScore W2564822114C2781375147 @default.
• W2564822114 hasConceptScore W2564822114C86803240 @default.
• W2564822114 hasConceptScore W2564822114C8891405 @default.
• W2564822114 hasIssue "21" @default.
• W2564822114 hasLocation W25648221141 @default.
• W2564822114 hasOpenAccess W2564822114 @default.
• W2564822114 hasPrimaryLocation W25648221141 @default.
• W2564822114 hasRelatedWork W1488560699 @default.
• W2564822114 hasRelatedWork W1724539479 @default.
• W2564822114 hasRelatedWork W2091543887 @default.
• W2564822114 hasRelatedWork W2119658998 @default.
• W2564822114 hasRelatedWork W2121615812 @default.
• W2564822114 hasRelatedWork W2125059689 @default.
• W2564822114 hasRelatedWork W2312663708 @default.
• W2564822114 hasRelatedWork W2767420145 @default.
• W2564822114 hasRelatedWork W3175832157 @default.
• W2564822114 hasRelatedWork W4237252206 @default.
• W2564822114 hasVolume "124" @default.
• W2564822114 isParatext "false" @default.
• W2564822114 isRetracted "false" @default.
• W2564822114 magId "2564822114" @default.
• W2564822114 workType "article" @default.